Compare TEX & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TEX | HALO |
|---|---|---|
| Founded | 1933 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.6B | 8.8B |
| IPO Year | 1994 | 2001 |
| Metric | TEX | HALO |
|---|---|---|
| Price | $64.45 | $68.04 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 11 |
| Target Price | $68.80 | ★ $78.18 |
| AVG Volume (30 Days) | 1.1M | ★ 1.2M |
| Earning Date | 05-01-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.07% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.33 | 2.56 |
| Revenue | ★ $5,421,000,000.00 | $151,862,000.00 |
| Revenue This Year | $47.68 | $28.24 |
| Revenue Next Year | $6.81 | $12.79 |
| P/E Ratio | ★ $19.02 | $26.18 |
| Revenue Growth | ★ 5.73 | N/A |
| 52 Week Low | $33.13 | $47.50 |
| 52 Week High | $71.50 | $82.22 |
| Indicator | TEX | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 57.74 | 57.42 |
| Support Level | $58.60 | $67.02 |
| Resistance Level | $70.58 | $74.92 |
| Average True Range (ATR) | 2.33 | 1.69 |
| MACD | 0.79 | 0.83 |
| Stochastic Oscillator | 93.53 | 96.68 |
Terex is a global manufacturer of aerial work platforms, materials processing equipment, and specialty equipment for the waste, recycling, and utility industries. Its current composition is a result of numerous acquisitions over several decades to focus on a smaller group of light construction and other vocational equipment, having divested a handful of underperforming businesses, particularly in cranes and other lifting equipment. These remaining segments see heavy demand in nonresidential construction (aerial work platforms—40% sales), aggregates/mining (materials processing—30% sales), environmental, waste/recycling and utilities (environmental solutions group—30% sales).
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.